Deep knowledge on
small-molecule drugs and
the 90,000 global patents
|Title:||Ophthalmic compositions comprising emedastine and methods for their use|
|Abstract:||Topical ophthalmic compositions comprising 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole and its ophthalmically acceptable acid addition salts have been found to be useful in treating allergic conjunctivitis and related ailments.|
|Inventor(s):||Yanni; John M. (Burleson, TX), Robertson; Stella M. (Arlington, TX), Okumura; Shigetoshi (Nara, JP), Tanaka; Hitoshi (Nara, JP), Saito; Tadayuki (Osaka, JP)|
|Assignee:||Alcon Laboratories, Inc. (Fort Worth, TX)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Japan||4-329216||Dec 09, 1992|
|Country||Document Number||Publication Date||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Spain||2137352||Dec 16, 1999|
|Australia||667613||Mar 28, 1996|
|Austria||185696||Nov 15, 1999|
|European Patent Office||0673250||Oct 20, 1999|
|World Intellectual Property Organization (WIPO)||9413299||Jun 23, 1994|
|This preview shows a limited data set|
Subscribe for full access, or try a free trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.